DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

July 25, 2006

FILE COPY

Steven Lieberman
Rothwell, Figg, Ernst & Manbeck
1425 K Street N.W.
Suite 800
Washington DC, 20005

Dear Mr. Lieberman:

Your petition requesting the Food and Drug Administration to determine whether Eloxatin (Oxaliplatin for Injection) 50 mg and 100 mg sterile lyophilized powder vials (NDA #21-492 has been withdrawn for safety or effectiveness reasons was, received by this office on 07/24/2006. It was assigned docket number 2006P-0299/CP1 and it was filed on 07/24/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0299

ACK!